ライフサイエンスコーパス: uterine leiomyoma

1 gning nonsurgical therapeutic strategies for uterine leiomyoma.

2 ly deleted in malignant myeloid diseases and uterine leiomyoma.

3 mangiomas, liver cysts, thyroid nodules, and uterine leiomyomas.

4 onance (MR) evaluation of known or suspected uterine leiomyomas.

5 n and progesterone, leading to the growth of uterine leiomyomas.

6 of women with cutaneous leiomyomas also had uterine leiomyomas.

7 ED12-LM) and HMGA2-overexpressing (HMGA2-LM) uterine leiomyomas.

8 in a syndrome called multiple cutaneous and uterine leiomyomas.

9 extended family with multiple cutaneous and uterine leiomyomas.

10 18, suggesting a pathogenesis in common with uterine leiomyomas.

11 n extremely common hormone-responsive tumor, uterine leiomyoma, a tumor with a significant impact on

12 mimic the effects of endogenous estrogens on uterine leiomyoma and may contribute to a complex hormon

13 NA-binding activity in protein extracts from uterine leiomyoma and normal myometrium tissues.

14 sor gene in the development of cutaneous and uterine leiomyoma and renal cell cancer in this syndrome

15 h HLRCC are at risk to develop cutaneous and uterine leiomyomas and an aggressive form of kidney canc

16 q22, in the minimal region deleted in 10% of uterine leiomyomas and in 10-20% of acute myeloid leukem

17 und causes thermocoagulation and necrosis in uterine leiomyomas and is feasible and safe, without ser

18 succinate dehydrogenase have been linked to uterine leiomyomas and paragangliomas, and cancer cells

19 the genetic locus for multiple cutaneous and uterine leiomyomas and the availability of an extended m

20 quencing and gene-expression profiling of 38 uterine leiomyomas and the corresponding myometrium from

21 duce a new, noninvasive treatment method for uterine leiomyomas and to present a comparison with othe

22 tiated mesenchymal tumors including lipomas, uterine leiomyomas, and pulmonary chondroid hamartomas.

23 Uterine leiomyomas are benign but affect the health of m

24 Uterine leiomyomas are benign tumors that can cause pain

25 Uterine leiomyomas are common benign smooth muscle tumor

26 Uterine leiomyomas are extremely common estrogen and pro

27 Multiple cutaneous and uterine leiomyomas are inherited as an autosomal dominan

28 Uterine leiomyomas are reported to be the most common be

29 s were shown to cause multiple cutaneous and uterine leiomyomas as well as hereditary leiomyomatosis

30 The authors investigated the risk of uterine leiomyoma associated with exposure to 2,3,7,8,-t

31 that of previously reported MED12 lesions in uterine leiomyoma but not those of other tumors.

32 d focused ultrasound surgery in treatment of uterine leiomyomas by using two treatment protocols.

33 progesterone stimulates the proliferation of uterine leiomyoma cells, the mechanism of progesterone a

34 ors could be seeded from a single lineage of uterine leiomyoma cells.

35 egrator of PR signaling and proliferation in uterine leiomyoma cells.

36 sc2-/- mouse embryonic fibroblasts, Eker rat uterine leiomyoma-derived Tsc2-deficient ELT3 cells, mut

37 men with a previous or coincident history of uterine leiomyoma, especially when no evidence of other

38 rospective trial performed in the context of uterine leiomyoma evaluation.

39 Uterine leiomyomas (fibroids or myomas), benign tumours

40 nstrated that this alteration alone promotes uterine leiomyoma formation and hyperplasia in both WT m

41 the genetic locus for multiple cutaneous and uterine leiomyomas, from 14 cM to an interval of 4.55 or

42 percent (41/46) of women with cutaneous and uterine leiomyomas had a total hysterectomy, 44% at age

43 (MED12) exon 2 variants are associated with uterine leiomyomas; however, the causality of MED12 vari

44 Uterine leiomyoma is an estrogen-responsive tumor, and t

45 ulator (SERM) for the potential treatment of uterine leiomyoma is described.

46 Uterine leiomyoma is the most common benign tumor in rep

47 Uterine leiomyoma is the most common tumor of the female

48 maging-guided focused ultrasound surgery for uterine leiomyomas is reported.

49 Myomectomy, the excision of uterine leiomyoma, is now commonly performed via minimal

50 genomic studies have identified subtypes of uterine leiomyoma (LM) with distinctive genetic alterati

51 Uterine leiomyomas (or fibroids) are the most common tum

52 These results suggest that in uterine leiomyomas PPARgamma activation is growth inhibi

53 terone receptor (PR) target genes in primary uterine leiomyoma smooth muscle cells.

54 This report describes a uterine leiomyoma specimen with an inv(6)(p21q15).

55 fects of estradiol and progesterone on these uterine leiomyoma subtypes emphasize the importance of s

56 al characteristics of the two most prevalent uterine leiomyoma subtypes, MED12-mutant (MED12-LM) and

57 aft assay was driven by progesterone in both uterine leiomyoma subtypes.

58 ne (FH) predispose to multiple cutaneous and uterine leiomyoma syndrome (MCL) and MCL associated with

59 In vitro studies have shown that uterine leiomyoma (UL) cells proliferate in response to

60 mmonly seen in benign smooth muscle tumor as uterine leiomyoma (UL).

61 (Tsc-2) tumor-suppressor gene predisposed to uterine leiomyomas, we show that an early-life exposure

62 major cause of chromosomal abnormalities in uterine leiomyomas; we propose that tumorigenesis occurs

63 Approximately 90% of cells in HMGA2-uterine leiomyoma were smooth muscle cells (SMC) with HM

64 gene responsible for multiple cutaneous and uterine leiomyomas, which, in turn, may provide key info

65 ted genetic locus for multiple cutaneous and uterine leiomyomas, with a maximum two-point LOD score o